Radioimmunotherapy with alpha-particle emitting radionuclides.

Journal Article (Review;Journal Article)

An important consideration in the development of effective strategies for radioimmunotherapy is the nature of the radiation emitted by the radionuclide. Radionuclides decaying by the emission of alpha-particles offer the possibility of matching the cell specific reactivity of monoclonal antibodies with radiation with a range of only a few cell diameters. Furthermore, alpha-particles have important biological advantages compared with external beam radiation and beta-particles including a higher biological effectiveness, which is nearly independent of oxygen concentration, dose rate and cell cycle position. In this review, the clinical settings most likely to benefit from alpha-particle radioimmunotherapy will be discussed. The current status of preclinical and clinical research with antibodies labeled with 3 promising alpha-particle emitting radionuclides - (213)Bi, (225)Ac, and (211)At - also will be summarized.

Duke Authors

Cited Authors

  • Zalutsky, MR; Pozzi, OR

Published Date

  • December 2004

Published In

Volume / Issue

  • 48 / 4

Start / End Page

  • 289 - 296

PubMed ID

  • 15640792

Electronic International Standard Serial Number (EISSN)

  • 1827-1936

International Standard Serial Number (ISSN)

  • 1824-4785

Language

  • eng